Australian Streptokinase Trial: Progress Report
The Australian Streptokinase Trial (ASK) Study was begun in June 1992 as an Australia-wide effort to assess the efficacy of intravenous streptokinase as a thrombolytic agent to minimize morbidity and mortality after acute ischemic stroke. The study was preceded by a pilot study of 52 patients among seven centers to assess the practicality of administering an agent within a 4-h time window in Australian hospitals. The results of the pilot study suggested that a major study was practical and that a thrombolytic agent administered acutely to patients with ischemic stroke was safe.
KeywordsIschemic Stroke Acute Ischemic Stroke Thrombolytic Agent Hemorrhagic Transformation Australian Capital
Unable to display preview. Download preview PDF.